Sun Pharma is the world's fifth largest generic pharmaceutical company and No. 1 in India. Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. US is the single largest market, accounting for about 50% turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including plants in US, Canada, Brazil, Mexico and Israel. In US, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).